Seroprevalence Investigation of Hepatitis B and Hepatitis B Core Antigen in Oncology Patients

Objectives: Hepatitis B virus (HBV) affects a significant part of society and is characterized by high mortality and morbidity. Hepatitis B affects approximately 350 million people worldwide, many of whom are chronic patients. Especially being under immunosuppressive therapy is a risk factor for the...

Full description

Saved in:
Bibliographic Details
Published inViral hepatit dergisi Vol. 26; no. 3; pp. 110 - 113
Main Authors Akdemir Kalkan, İrem, Demirci, Ayşe, Çınar, Güle, Çelen, Mustafa Kemal
Format Journal Article
LanguageEnglish
Published Ankara Galenos Publishing House 01.12.2020
Subjects
Adaptive immunity
Antigens
Antiviral drugs
Cancer therapies
Chemotherapy
Disease prevention
Hepatitis B
Hospitals
Immunosuppressive agents
Infections
Infectious diseases
Oncology
Patients
Serology
Turkey
Online AccessGet full text

Cover

More Information
Summary:Objectives: Hepatitis B virus (HBV) affects a significant part of society and is characterized by high mortality and morbidity. Hepatitis B affects approximately 350 million people worldwide, many of whom are chronic patients. Especially being under immunosuppressive therapy is a risk factor for the reactivation of the disease. The aim of this study was to investigate the seroprevalence of HB in oncology patients. Materials and Methods: In this study, the seroprevalences of hepatitis B surface antigen (HBsAg), anti-hepatitis C virus, anti-HBs, and anti-hepatitis B core antibody (anti-HBc) immunoglobulin G (IgG) were retrospectively evaluated from the medical records of 84 patients who were diagnosed of cancer, and were admitted to the outpatient clinic of medical oncology in the Batman State Hospital within a period of one year (between January and December 2017). Results: Anti-HBc IgG was positive in 44 patients (52.2%),16 (36.4%) have received treatment for the prevention of HBV reactivation six of these patients were HBsAg positive No reactivation and no side effects occur in patients who received prophylactic antiretroviral treatment. Conclusion: In our study, both the proportion of patients with HBsAg positivity and the proportion of patients with natural immunity were found to be slightly higher than those in Turkey and worldwide. No patients with HB reactivation is important evidence of necessity effectiveness of prophylactic antiviral treatment.
ISSN:1307-9441
2147-2939
DOI:10.4274/vhd.galenos.2020.2019.0036